

ANSWERING REVIEWERS

August 3, 2021

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 67003_Auto_Edited.docx).

Title: New horizons for uncommon mutations in non-small cell lung cancer: *BRAF, KRAS, RET, MET, NTRK, HER2*

Authors: Olmedo E, Cervera R, Cabezón-Gutiérrez, Lage Y, Corral E, Gómez-Rueda A, Mielgo-Rubio X, Trujillo-Reyes JC and Couñago F.

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 67003

The manuscript has been modified according to the recently published evidence and the reviewer suggestions:

- 1) The manuscript has been updated
- 2) The language has been polished
- 3) Modifications were done according to the reviewer suggestions as follows:

Comment 1: The authors summarized the therapeutic advances which target genes uncommonly mutated in NSCLC. However, the info in this review appears not up-to-date. For sample, there are FDA approved therapies for NSCLC harboring BRAF V600E and Ret-fusions, and on 02.17.2021, The FDA granted priority review to sotorasib to treat patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). All these information was not covered in the review. Also BRAF Non-V600 mutations were not covered in the review.

Response: We have updated the manuscript with the latest info about all drivers. Efficacy data is summarized in tables.

Overall, we would like to thank the reviewer remarks which have help us to improve substantially our manuscript.

Thank you again for publishing our manuscript in *World Journal of Clinical Oncology*.

Sincerely yours,

Olmedo E, PhD, MD,

Department of Medical Oncology, Ramón and Cajal University Hospital, Carretera Colmenar Viejo Km
9.1 CP 28034 Madrid Spain. mariaeugenia.olmedo@salud.madrid.org

Tel: +34-913368263 **Fax:** +34-913369181